PPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility by Minge, Cadence E. et al.
Hindawi Publishing Corporation
PPAR Research
Volume 2008, Article ID 243791, 19 pages
doi:10.1155/2008/243791
ReviewArticle
PPAR Gamma: Coordinating Metabolic and Immune
Contributions to Female Fertility
Cadence E. Minge, Rebecca L. Robker, and Robert J. Norman
Research Centre for Reproductive Health, School of Paediatrics and Reproductive Health, The University of Adelaide,
South Australia 5005, Australia
Correspondence should be addressed to Robert J. Norman, robert.norman@adelaide.edu.au
Received 2 April 2007; Accepted 2 July 2007
Recommended by Pascal Froment
Peroxisome proliferator-activated receptor gamma (PPARG) regulates cellular functions such as adipogenesis and immune cell
activation. However, new information has indicated additional roles of PPARG directing the cyclic changes that occur within
ovarian tissue of female mammals, including those that facilitate the release of oocytes each estrous cycle. In addition to ovarian
PPARG expression and function, many PPARG actions within adipocytes and macrophages have additional direct and indirect
implications for ovarian function and female fertility. This encompasses the regulation of lipid uptake and transport, insulin
sensitivity, glucose metabolism, and the regulation of inﬂammatory mediator synthesis and release. This review discusses the
developing links between PPARG activity and female reproductive function, and highlights several mechanisms that may facilitate
such a relationship.
Copyright © 2008 Cadence E. Minge et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1. INTRODUCTION
Since its initial identiﬁcation in the early 1990’s, peroxi-
some proliferator-activated receptor gamma (PPARG) has
been primarily recognised as a regulator of cellular func-
tions such as adipogenesis and immune cell activation. How-
ever, some recent reviews have discussed additional roles of
PPARG directing the cyclic changes that occur within ovar-
ian tissue of female mammals, including those that facili-
tate the release of oocytes each estrous cycle [1–4]. In ad-
dition to ovarian PPARG expression and function, many
PPARG actions within adipocytes and macrophages have ad-
ditional direct and indirect implications for ovarian function
and female fertility. For instance, PPARG, through activa-
tion by thiazolidinediones (TZDs), is known to regulate the
metabolism of lipids, providing both self-regulatory PPARG
transcriptional mechanisms, and stimulating an increase in
adipogenesis. Whilst the net volume of adipose tissue carried
within an individual can inﬂuence reproductive potential,
genes associated with lipid metabolism are also important
for ovarian cells directly. As a result, PPARG has the poten-
tial to inﬂuence the cellular operations of follicles contain-
ing oocytes and, consequently, the health of those oocytes re-
leased. Likewise, the PPARG regulation of insulin sensitivity,
downstream signalling pathways, and ultimately glucose up-
take are likely to be also vitally important for normal ovarian
function and overall female fertility.
Similarly, PPARG regulation of macrophage function has
been addressed in vitro and within the context of the adi-
pose tissue for many years; but appropriate activity of resi-
dent immune cells is also a prerequisite for normal ovarian
function, as they are required for tissue remodelling facilitat-
ingovulation,luteinization,andluteolysis[5].Therefore,not
only are adipose/circulating macrophage-sourced inﬂamma-
tory mediators sensed by ovarian cells, but these mediators,
when produced locally by the ovary, may inﬂuence the ovar-
ian function in an autocrine fashion.
This review aims to provide evidence for how PPARG-
regulated pathways inﬂuence the female’s ability to pro-
duce healthy, developmentally competent oocytes. This is
impacted by cellular function operating primarily at the lo-
cal ovarian level, either directly acting upon the oocyte it-
self, or inﬂuencing the supporting ovarian cells that supply
the oocyte with hormonal signals and nutrients. In addition,2 PPAR Research
Luteal: expression inversely
related to progesterone
production: low in newly
formed luteal tissue, increasing
ascorpus luteum ages, and
P4 production declines [18].
Macrophage: PPARG expression reﬂective of immune activation status. Relatively high throughout
follicle growth, transiently suppressed at ovulation, and high as luteinization occurs [1].
Theca: low to negative
expression [2].
Granulosa: estrous cycle stage dependent: strong
expression in primary to pre-ovulatory follicles, which
declines signiﬁcantly after LH surge [14].
Oocyte: species dependent: moderate (bovine,
[16,9])/trace (xenopus, [17]) /negative (rodent [1,15])
LH
Figure 1: Overview of PPARG expression by speciﬁc ovarian cell types, as follicular development progresses from early antral and preovu-
latory follicle to postovulatory corpus luteum.
signals from extraovarian tissues, in particular adipose tissue
and the circulating and/or resident immune cells, also exert
powerful inﬂuences over the normal function of the ovary.
These concepts of overlapping inﬂuence on female fertil-
ity are particularly important when we consider conditions
of reduced and impaired fertility such as polycystic ovary
syndrome(PCOS),aswellasreductionofreproductivefunc-
tion associated with excessive bodyweight and insulin resis-
tance. In these situations, profound dysregulation of both
metabolic and immune signalling pathways exacerbate ovar-
ian perturbations, which are often successfully treated with
administration of PPARG-activating pharmaceuticals.
2. PPARG GENE EXPRESSION
Successful mammalian reproduction requires a female body
adequately, but not excessively, nourished, equipped to pro-
duce healthy eggs and to supply a growing fetus with suﬃ-
cientenergy.Inthisway,manytissueswithinthefemalebody
areabletoinﬂuencetheleveloffertility.TheextentofPPARG
expression and its temporal regulation within these tissues
can provide an interesting insight into the role of PPARG in
female fertility.
2.1. OvarianPPARG
Within the ovary, processes that are modulated by the PPAR
superfamily, particularly PPARG, are among the most crit-
ical to normal ovarian function (Figure 1). Steroidogenesis,
tissue remodelling, angiogenesis, lipid metabolism, immune
cell activation, and production of proinﬂammatory media-
tors are all, to some extent, controlled by the presence and
activity of the PPAR nuclear receptors. All three PPAR iso-
types have been identiﬁed in the ovary of many species in-
cluding the rat [2, 6], mouse [7], pig [8], sheep [9], cow
[10, 11], and human [12, 13]. Localisation of these nuclear
receptors has been established by both in situ hybridisa-
tion and immunohistochemistry [6]. Transcripts for PPAR
alpha (PPARA) have been identiﬁed in immune cells and
cells in the theca and stroma, whilst PPAR delta (PPARD)
is found across all ovarian compartments [2]. Ovarian ex-
pression of both PPARA and PPARD is relatively stable
across the ovulatory cycle, which suggests these isotypes are
likely involved in regulating basal ovarian functions. PPARG
is expressed strongly in the granulosa cells (primarily re-
sponsible for both estradiol production and the regulation
of follicular ﬂuid content), and lessstrongly in the thecal-
region (site of androgen precursor production for granu-
losa estradiol synthesis) and luteal cells (postovulatory pro-
gesterone production) in the ovaries of rodents and rumi-
nants [1, 2, 9, 14]. PPARG is detected earlyin folliculogene-
sis, and in contrast to PPARA and PPARD isotypes, its ex-
pression is dynamic, increasing until the large folliclestage
[9], followed by downregulation in response to the LH surge
[2].
Within the oocyte itself, PPARG expression seems to be
dependent upon species, as moderate expression has been
reported in ruminants [16] ,t r a c el e v e l si nX e n o p u so o c y t e s
[17], and undetectable expression in rodents [1, 18]. It has
not yet been investigated within the human oocyte.Cadence E. Minge et al. 3
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Figure 2:(a)Thegenomicstructureofthe5  endofthehumanPPARGgene.Exons1-6arecommon.ExonsA1andA2areuntranslated,and
exon B is translated, giving rise to two diﬀerent proteins corresponding to the G1 or G2 transcripts. (b) The domain structure of PPARG1
and G2 isoforms with the positioning of mutations or polymorphisms resulting in substituted amino acid residues, and altered protein
functions. DBD, DNA-binding domain; LBD, Ligand-binding domain. (Figure adapted from Sundvold and Lien[33], Tsai and Maeda [37],
and Stumvoll and H¨ aring [38]).
2.2. ExtraovarianPPARG
The highest level of mammalian PPARG expression is found
within adipose tissue [19, 20], and activation of this adipose
PPARG is suﬃcient [21] and essential to induce adipogene-
sis [22, 23]. Adiposity is also a key regulator of female fer-
tility, aﬀecting multiple aspects of the reproductive axis in
women [24, 25]. Many of the adipocyte-sourced factors that
are under PPARG control, such as the production of non-
esteriﬁed free fatty acids, have widespread eﬀects including
ovarian targets [26–28]. In addition, any activation of adi-
pose PPARG that may inﬂuence the amount and activity of
adipocytes/adipokines can subsequently impact upon repro-
ductive potential [29].
Both the ovary and adipose tissue are comprised of
a considerable proportion of immune cells, in particular
macrophages. Macrophages recruited into tissues are an im-
portant source of many inﬂammatory mediators that have
functions both locally and systemically. Within the ovary,
macrophage contribution to the pool of functional PPARG
has been assessed [1]. TZD treatment has also been found
to aﬀect adipose-recruited macrophages, by increasing the
rate of apoptosis, providing a subsequent reduction in the
number of proinﬂammatory cytokine-producing cells [30].
Improvements to the chronically inﬂamed proﬁle of women
with PCOS may well go some way in explaining the beneﬁ-
cialsystemiceﬀectsofPPARGactivationinsuchpatients(see
Sections 3.2 and 4.4).
2.3. MutationsinPPARGnegativelyinﬂuence
femalefertility
The PPARG gene contains 9 exons, and spans more than
100kb [31]( Figure 2(a)). There are at least 4 isoforms of
PPARG,resultingfromtheuseofdiﬀerentinitiatormethion-
ines [31–33], which are believed to be involved in regulated
gene expression in speciﬁc cells and tissues. PPARG1, ex-
pressed utilizing the untranslated exons A1 and A2, is 477
amino acids long, and is expressed at low levels in many
tissues [34]. PPARG2 contains the translated exon B, and
as a result is 28 amino acids longer than PPARG1 [35].
This isotype is expressed selectively in white adipose tissue,
colonic epithelium, and macrophages [36]. PPARG3, which
contains only exon A2, is found only in the large intestine
and macrophages [31]. PPARG4 is limited to exon 1-6 com-
mon to all isotypes [33]. There have been numerous studies
into theeﬀectsofgenetic variability ofPPARGgenesequence
a n de x p r e s s i o n ,i nb o t hr o d e n tm o d e l sa n dh u m a np a t i e n t s
(Figure 2(b), Table 1).
Work initiated in rodent knockout models revealed that
total PPARG−/− mutants display two independent lethal
phases [23]. Firstly, PPARG deﬁciency interferes with ter-
minal diﬀerentiation of the trophoblast cells and with pla-
cental vascularization, leading to myocardial thinning, and
death by embryonic day 10. When PPARG null embryos are
provided with a wild-type placenta, this cardiac defect was
corrected permitting delivery, although postnatal patholo-
gies (including multiple haemorrhages and lipodystrophy)
resultedinlethality.Tocircumventsuchrestrictions,theCre-
loxP system can be applied, where Cre recombinase was un-
der the control of the whey acidic protein (WAP) or mouse
mammary tumour virus (MMTV) promoters. This causes
PPARG gene deletions speciﬁc to secretory and hematopoi-
etic tissues (alveolar epithelial cells of mammary tissue, sali-
vary gland cells, oocytes, granulosa cells, megakaryocytes,
and B- and T-cells) [50]. The results of this study revealed
an important PPARG role in fertility: although the mutant
mice appeared to ovulate normally, they exhibited reduced4 PPAR Research
Table 1: Phenotypes and reproductive eﬀects associated with PPARG mutations in mice and humans. Abbreviations used: ART: artiﬁcial re-
productive technology; BAT: brown adipose tissue; BMI: body mass index; HbA(1C): haemoglobin A1C; KO: knock-out; PCOS: polycystic
ovary syndrome; T2DM: Type 2 Diabetes Mellitus; TG: Triglycerides; WAT: white adipose tissue.
Species Genetic
Abberation Outcome Eﬀect on female fertility Reference
Mouse
Global
PPARG−/− Neonatal death — [23]
Global
PPARG−/+
Improved insulin
sensitivity Fertile [39]
Mammary,
epithelium,
ovary, B- and
T-cell null
Ovarian dysfunction and
abrogated mammary
development
30% of animals completely
infertile, remainder had
delayed conception,
reduced litter size
[7]
PPARGhyp/hyp:
WAT BAT, liver,
and muscle null.
Normal birthweight but
subsequent growth
retardation, lipodystrophy,
hyperlipideamia, and mild
glucose intolerance
Heterozygote matings
produce normal sized
litters, but homozygote
matings result in reduced
litter size.
[40]
Human
Pro12Ala (34C
> G), PPARG2
only.
Ala allele ↓ PPREs aﬃnity,
↓ PPARG transactivation.
↑ Insulin sensitivity in
some studies, conﬂicting
reports on association with
BMI.
Possible relationship with
PCOS. In wider, non-PCOS
population Ala allele
associated with
↓ testosterone production
[41–43]
Pro115Gln
(344G > T),
PPARG2 only.
Constitutively activated
PPARG, ↑ adipocyte
diﬀerentiation. Severe
obesity, 3/4s u b j e c t sT 2 D M .
Fertility not assessed. [44]
His447His
(1431C > T)
T allele may increase
adipocyte diﬀerentiation.
Presence of T allele
associated with ↑ BMI, and
insulin sensitivity.
Ta l l e l em o r ec o m m o ni n
PCOS compared to
BMI-matched controls. T
allele associated with
↓ testosterone.
[43, 45]
Pro467Leu
(1647C > T)
Mutation in LBD,
↓ coactivator recruitment
and downstream
transactivation. ↓ Basal
gene activity.
Lipodystrophy but normal
BMI, severe insulin
resistance and
hypertension. One carrier
(from 4) responsive to
rosiglitazone therapy.
Oligomenorrhoea and
hirtsutism, required ART
for 1st pregnancy,
complicated by
pre-eclampsia and induced
labour. 2nd pregnancy
spontaneously conceived,
with pre-eclampia, preterm
emergency caesarean, and
neonatal infant death.
[46, 47]
Val290Met
(1115G > A)
Mutation aﬀects LBD,
profound blockage of
transcriptional activation.
Similar phenotype to
P467L. Unresponive to
rosiglitazone therapy.
Primary amenorrhoea,
hirsutism, acanthosis
nigricans, and
hypertension.
[46, 47]
Phe388Leu
(1164T > A)
↓ PPARG-ligand binding,
↓ basal transcriptional
activity. Lipodystrophic
and hypertensive with
↑ TG. Hyperinsulinemic,
later T2DM.
Irregular menses, and
bilateral polycystic ovaries
treated with
salpingo-oopherectomy.
Prior to this carried two
pregnancies.
[48]
Arg397Cys
(1273C > T)
Mutation in LBD,
unknown eﬀect on PPARG
function. Lipodystrophic,
↑ TG and T2DM.
Hirsutism but no other
indications of
hyperandrogenism.
Delayed menarche, but
regular menses.
[49]Cadence E. Minge et al. 5
progesterone secretion as well as impaired implantation. In-
terestingly,fertilityisaﬀectedevenwhenthelesioninPPARG
expression is restricted to extraovarian sites, as homozygote
matings of PPARhyp/hyp mutants, lacking PPARG expression
in white and brown adipose tissue, liver, and muscle, had re-
duced litter size [40].
Examinations of naturally occurring human polymor-
phisms have focussed on susceptibility to Type II diabetes,
insulinsensitivity,andobesity,andtodateatleastsevenpoly-
morphisms within the PPARG gene have been described.
The Pro12Ala polymorphism is located in exon2, and is
only translated within the adipose tissue-, macrophage-, and
colonic epithelium-speciﬁc PPARG2 isotype. The Pro12 al-
lele is carried by approximately 85% of certain regional pop-
ulations [51], and a single nucleotide mutation (C→G) leads
tothe substitutionof anAlaamino acid[41].PPARGprotein
produced by the Ala12 allele shows reduced in vitro aﬃnity
for PPAR response elements (PPREs) in target gene proxi-
mal promoters, and subsequently has reduced PPARG trans-
activation [41]. This PPARG SNP was extensively studied,
following initial reports that it was strongly associated with
bodyweight and insulin sensitivity [41], and the eﬀect of the
Ala12 mutation on PCOS symptoms has been closely stud-
ied, although some speciﬁc conclusions are diﬃcult to reach.
There are conﬂicting reports regarding the eﬀect of this allele
on BMI: either linked with increased BMI [45, 52–55], lower
BMI [41, 56–59], or not associated at all [45, 60–64]. Cur-
rent assumptions are that diﬀerential environmentalinterac-
tions between populations can modify the function of this
polymorphism. However, the relationship between Pro12Ala
and insulin sensitivity appears more conclusive. Populations
ofwomenpositiveforAla12andPCOShavelowerfastingin-
sulin, reduced measures of systemic insulin resistance, lower
insulin secretion, and lower hirsutism scores than women
without the allele [54, 65, 66]. Consequently, the frequency
o ft h i sa l l e l ei sm u c hl o w e ri ng r o u p sc a t e g o r i s e da sP C O S
[54, 65, 67]. It appears that the Pro12Ala polymorphism of
the PPARG gene may be a modiﬁer of insulin resistance in
women with PCOS, which can have a profound inﬂuence on
fertility (see Section 4.1).
Another PPARG2-speciﬁc polymorphism is the rare
Pro115Gln substitution in exon 3 that results in permanent,
ligand independent activation [44]. This induces excessive
adipocyte diﬀerentiation, and as a result the 4 individuals
knowntocarrythis(nonfamilial)SNPsuﬀerextremeobesity
[44], although present with only moderate metabolic com-
plications including Type 2 Diabetes. The reproductive im-
plications of hyperactive PPARG2 have not been addressed
in these subjects.
All other reported polymorphisms are located in regions
common to both PPARG1 and PPARG2. The His447His
polymorphisms resulting from a C to T substitution at nu-
cleotide 1431 in exon 6 is a silent polymorphism that en-
codes histidine with either allele [55]. Also referred to as
the C161T polymorphism, it is proposed that this substitu-
tion may modulate expression of PPARG by altering mRNA
processing or translation, leading to increased adipocyte dif-
ferentiation. Subsequently, carriers of the T allele have el-
evated BMI. The T allele is also more common in women
with PCOS compared to non-PCOS BMI-matched controls
[45], and therefore has suspected involvement in the high in-
cidenceofobesityinPCOSpopulation.However,bothPCOS
subjects and controls with T allele appear to be protected
from other complicating symptoms of obesity, having bet-
ter insulin sensitivity in addition to lower circulating testos-
terone.
The remaining polymorphisms are all extremely rare and
restricted to single families.
Reported by Barroso et al. [46]a n dS a v a g ee ta l .[ 47],
there is a PPARG1 Pro467Leu substitution in the region
required for ligand-dependent transactivation (PPARG2
residue 495) which results in impaired coactivator recruit-
ment and downstream transactivation. This mutation also
inhibits basal gene activity and has been found within 4
members of a single family spanning 3 generations. Medi-
cal histories reveal that in addition to lipodystrophy and hy-
pertension (both frequently associated with PPARG muta-
tions), the female carrier also experienced oligomenorrhea
and hirsutism, and required ART intervention to conceive.
This, and a subsequent spontaneously conceived pregnancy
were both complicated with severe pre-eclampsia. Treatment
of the male carrier with rosiglitazone (8mg/day) was found
to normalise chronic hyperglycaemia after 6 months, sug-
gesting that the mutant PPARG protein is still able to be ac-
tivated by exogenously sourced ligands, indicating the phe-
notypic proﬁle of these subjects results from abnormal basal
and endogenously activated PPARG activity.
Also identiﬁed by this study was a similarly positioned
PPARG1 Val290Met mutation (PPARG2 residue 318) in a
single female individual. This mutation results in a pro-
found loss of PPARG function evidenced by both in vitro
reporter gene activity, and in vivo response to rosiglitazone.
Experiencing comparable metabolic complications to sub-
jects with the Pro467Leu substitution, this individual also re-
ported primary amenorrhoea, hirsutism, and acanthosis ni-
gricans. Implications of these gynaecological and endocrine
aberrations relating to conception and pregnancy have not
been reported.
Another loss-of-function mutation is the phenylalanine
to leucine substitution at position 388 (reported with re-
specttoPPARG2,thesubstitutioncorrespondstoresidue360
in PPARG1) found in 4 individuals from 3 generation of a
single family [48]. Despite the reduction in normal PPARG
function, concurrent treatment of one individual with both
metformin and rosiglitazone (8mg daily) provided eﬀective
glycemic control. Two of the aﬀected individuals were female
(46-year-old mother and her 22-year-old daughter), with the
older individual experiencing a history of irregular menses
and polycystic ovarian disease, eventually treated with bilat-
eralsalpingo-oophorectomy.Atthetimeofstudy,thedaugh-
terdidnothaveanysigniﬁcantmedicalproblems(otherthan
diet-controlled hyperinsulinemia and mild type IV hyper-
lipoproteinia), with regular menses and no polycystic ovar-
ian pathology observed.
A heterozygous arginine to cysteine mutation at position
397 in PPARG1 (corresponding to residue 425 in PPARG2)
was identiﬁed in a 64-year-old woman in 2002 by Argarwal
and Garg [49]. Although the eﬀect on PPARG functionality6 PPAR Research
has not been explicitly described, but the mutation lies in a
region of the protein that forms a salt-bridge, and as a result,
the mutated form may lack proper protein conﬁguration.
The Arg397Cys substitution was associated with lipodystro-
phy, elevated triglycerides, and early-onset Type 2 Diabetes.
In addition, although pregnancy was never sought, moder-
ate hirsutism as well as a history of delayed menarche (age
18) and subsequently irregular menstrual cycles were re-
ported.
Overall, these studies demonstrate that PPARG precisely
controls various aspect of systemic metabolism in humans.
As female fertility is also disrupted in a signiﬁcant number
of these patients, it is likely that PPARG regulates female re-
production either directly, by intrinsic actions within repro-
ductive organs such as the ovary, or indirectly via the myr-
iad eﬀects on metabolic tissues such as adipose and liver.
To better deﬁne links between the metabolic and reproduc-
tive consequences observed in so many of these PPARG mu-
tations, it would be interesting to recapitulate, in a tissue-
speciﬁc manner, some of these PPARG genetic aberrations in
mice.
3. LIGANDS
Together with expression of PPARG itself, availability of lig-
ands is a primary regulating factor determining the ability
of PPARG to inﬂuence target gene expression. Ligands can
be produced endogenously, providing physiological signiﬁ-
cance, or sourced exogenously, as therapeutic factors given
to target speciﬁc metabolic and reproductive symptoms.
3.1. Endogenousligands:physiological
functionofPPARG
All PPARs bind and are activated by naturally occurring
fatty acids and their metabolites [68], thus acting as fatty
acid-activated receptors that function as key regulators of
glucose and cholesterol metabolism. The precise nature of
endogenous PPARG ligand binding and activation remains
poorly deﬁned and more research is needed in this area.
However, the potential for important physiological ovarian
PPARG activation is considerable, as many natural ligands
have been shown to be present within the ovary, and pro-
ducedlocallybyovariancells.Includedinthislistareω3-and
ω6-polyunsaturated fatty acids (PUFAs) such as the essen-
tial fatty acids linoleic acid, linolenic acid, arachidonic acid,
and eicosapentanoic acid ([69]a n dr e v i e w e d[ 34]). Addi-
tional PPARG agonists such as prostaglandin metabolites of
these substances and immunologically-derived eicosanoids
are also produced within the ovarian environment in
a hormonally regulated manner, with elevated produc-
tion as ovulation progresses [70–73]. It is possible that
PPARG may have a role in the feed-forward production of
eicosanoid ligands, based on identiﬁcation of a PPRE in the
prostaglandin-endoperoxide synthase 2 (a.k.a. COX-2) pro-
moter [74], which would facilitate ampliﬁed production of
pro-ovulatory prostaglandins.
3.2. Exogenousligands:therapeuticapplication
ofPPARGactivation
As information emerges regarding the endogenous roles for
naturally activated PPARG within the ovarian follicular envi-
ronment, other evidence of PPARG involvement with ovar-
ian function comes from reports utilising synthetic PPARG
ligands, speciﬁcally, administration of TZDs to women diag-
nosed with PCOS (Table 2).
PCOS is the leading cause of infertility and menstrual
irregularities in women of reproductive age and is charac-
terised by chronic hyperandrogenic anovulation [90]. This is
thought to be due, in general, to hypothalamic-pituitary axis
dysregulation causing elevated basal LH levels that overstim-
ulatecellsofthethecainterna[91].Insulinresistancealsoap-
pears to contribute to the syndrome in many instances [92],
as the pituitary responds to elevated plasma levels of insulin
to augment LH release [91].
The potential merits of applying TZDs to improve repro-
ductive outcomes in infertile PCOS women was ﬁrst demon-
stratedbyAzzizetal.[93].Sincethen,treatmentofPCOSpa-
tients with the TZDs rosiglitazone or pioglitazone have been
shown to not only improve insulin action in peripheral tis-
sues, attenuate hyperinsulinemia, and lower circulating lev-
els of lipids [92, 94], but also to improve a range of repro-
ductive outcomes particularly circulating sex hormone lev-
els, and ovulation rate [77, 88, 90, 95–97] (see recent reports
summarised in Table 2).
The beneﬁcial eﬀects of TZDs on ovarian PCOS symp-
toms were ﬁrst attributed to improvements in defective in-
sulin action and secretion [92]. However, actions upon var-
ious ovarian cells directly illustrated both in vitro [1, 9, 14,
98, 99] and in vivo [100, 101] conﬁrms a direct interaction
between these compounds and ovarian PPARG.
Particular focus has been directed upon the eﬀect of
PPARG activation on the synthesis of ovarian steroid hor-
mones and the expression of many rate-limiting steroido-
genic enzymes has been investigated.
(1) Steroidogenic acute regulatory protein (StAR): facili-
tates that rapid mobilization of cholesterol for initial
catalysistopregnenolonebytheP450-sidechaincleav-
age enzyme located within the mitochondria [102].
It has been recently reported that both rosiglitazone
andpioglitazonesigniﬁcantlyupregulateStARprotein
synthesis by human granulosa cells in vitro [103].
(2) 3β-hydroxysteroid dehydrogenase (3β-HSD): catalyses
the conversion of pregnenolone to progesterone by
luteal cells [104]. Work on porcine granulosa cells has
foundthattroglitazonecompetitivelyinhibits 3β-HSD
enzyme activity within these cells [99].
(3) Steroid17-alpha-hydroxylase(P450c17):convertspro-
gesteronetoandrogenwithinovarianthecacells[105].
Conﬂicting reports have arisen regarding the eﬀect of
TZDs on the expression and activity of this enzyme,
manyofwhichmaybeartefactsofvariousculturecon-
ditions. P450c17 mRNA production has been found
to increase following porcine thecal cell exposure to
TZDs [8], whilst other reports indicate suppressionCadence E. Minge et al. 7
Table 2: Summary of reports published within the past 2 years on the use of PPARG activating agents for reproductive symptoms. Abbreviations
used: AUC, area under the curve; BMI body mass index; CC clomiphene citrate; DHEA-S dehydroepiandrosterone sulfate; E2, estradiol; FAI,
free androgen index; FSH, follicle-stimulating hormone; GnRH, gonadotropin releasing hormone; HbA(1C), haemoglobin A1C; HDL-C,
high density lipoprotein-cholesterol; HOMA, homeostasis model of assessment for insulin sensitivity; IGF1 insulin-like growth factor 1;
IGFBP-1/3, insulin-like growth factor binding protein 1 or 3; LDL-C, low density lipoprotein-cholesterol; LH, luteinizing hormone; OGTT,
oral glucose tolerance test; PCOS, polycystic ovary syndrome; QUICKI, quantitative insulin-sensitivity check index; SHBG, sex hormone
binding globulin; T, testosterone; WHR, waist to hip ratio.
Reference: Rautio et al. [75] and Rautio et al. [76]
Patient proﬁle: Overweight but not obese PCOS (n = 30)
PPAR agonist: Rosiglitazone (4mg once daily for 2 weeks then 4mg twice daily for 16 weeks)
Metabolic outcomes:
Serum C-reactive protein levels, leukocyte count, and alanine aminotransferase enzyme activity
decreased, but lipid and blood pressure did not change. Glucose tolerance and peripheral insulin
response normalized in the rosiglitazone group.
Reproductive outcomes: Rosiglitazone improved menstrual cyclicity, SHBG levels; and decreased serum levels of
androstenedione, 17-hydroxyprogesterone (17-OHP), DHEA and DHEA-S.
Reference: Rouzi and Ardawi [77]
Patient proﬁle: Obese PCOS (n = 12)
PPAR agonist: Rosiglitazone (4mg twice daily for 3 cycles, CC administered for 5 days starting 3 days after
rosiglitazone initiated)
Metabolic outcomes:
No changes in fasting plasma glucose or HbA(1C) or IGFBP-3 values. Fasting serum insulin,
DHEA-S, androstenedione, and IGF-1 levels decreased signiﬁcantly and IGFBP-1 exhibited
signiﬁcant increases.
Reproductive outcomes:
Total-T, free-T, LH, and SHBG decreased. Follicular development and ovulation rate increased,
trend for increased pregnancy rate in group receiving short-term administration of rosiglitazone
compared to matched control receiving metformin.
Reference: Mitkov et al. [78]
Patient proﬁle: Obese, insulin resistant PCOS (n = 15)
PPAR agonist: Rosiglitazone (4mg/day for 12 weeks)
Metabolic outcomes: Hyperinsulinemia and insulin resistance normalized.
Reproductive outcomes: Total-T and FAI proﬁle tended to normalise. Number of women with oligomenorrhea was
reduced by 67%
Reference: Cataldo et al. [79]
Patient proﬁle: Insulin resistant PCOS (n = 11–16/group)
PPAR agonist: R o s i g l i t a z o n e( 2 ,4o r8m g / d a yf o r1 2w e e k s )
Metabolic outcomes: Steady state plasma glucose declined and hyperinsulinemia fell in a dose-dependent manner.
Reproductive outcomes:
Serum LH, total-T, and free-T were unchanged; SHBG increased. Ovulation occurred in 55%,
without signiﬁcant dose dependence. Before and during treatment, ovulators on rosiglitazone
had lower circulating insulin and free-T and higher SHBG than nonovulators.
Reference: Lemay et al. [80]
Patient proﬁle: Overweight, insulin resistant PCOS (n = 15)
PPAR agonist: Rosiglitazone (4mg/day for 6 months)
Metabolic outcomes: Plasma insulin, insulin resistance indices and insulin AUC in response to OGTT all decreased
compared to controls receiving antiandrogenic estrogen-progestin. Eﬀect on lipids was limited.
Reproductive outcomes: No signiﬁcant eﬀect on androgens or hirsutism.
Reference: Garmes et al. [81]
Patient proﬁle: Obese insulin resistant PCOS (n = 15)
PPAR agonist: Pioglitazone (30mg/day for 8 weeks)
Metabolic outcomes: Insulin response to OGTT signiﬁcantly decreased.
Reproductive outcomes: Total-T and free-T levels decreased, SHBG increased, and LH response to GnRH stimulation
decreased.
Reference: Yilmaz et al. [82–84]
Patient proﬁle: Obese or lean PCOS (n = 20 obese, n = 20 lean)
PPAR agonist: Rosiglitazone (4mg/day for 12 weeks)
Metabolic outcomes: Indices of oxidative stress improved. HOMA, insulin AUC, fasting insulin and C-peptide levels
decreased signiﬁcantly. Glucose/insulin ratio and BMI increased8 PPAR Research
Table 2: Continued.
Reference: Rautio et al. [75] and Rautio et al. [76]
Patient proﬁle: Overweight but not obese PCOS (n = 30)
PPAR agonist: Rosiglitazone (4mg once daily for 2 weeks then 4mg twice daily for 16 weeks)
Metabolic outcomes:
Serum C-reactive protein levels, leukocyte count, and alanine aminotransferase enzyme activity
decreased, but lipid and blood pressure did not change. Glucose tolerance and peripheral insulin
response normalized in the rosiglitazone group.
Reproductive outcomes:
Rosiglitazone improved menstrual cyclicity, SHBG levels; and decreased serum levels of
androstenedione, 17-hydroxyprogesterone (17-OHP), DHEA and DHEA-S.
Reproductive outcomes:
Seurm levels of free-T, androstenedione, and DHEA-S decreased signiﬁcantly. Menstrual
disturbances improved in 61.5% of lean and 53.8% of obese patients. In a second cohort of
patients, menstrual cycles became regular in 87.8%.
Reference: Tarkun et al. [85]
Patient proﬁle: Young, lean PCOS (n = 31)
PPAR agonist: Rosiglitazone (4mg/day for 12 months)
Metabolic outcomes:
Fasting insulin and insulin resistance indices signiﬁcantly improved. No changes in BMI, waist
circumference, serum total cholesterol, or LDL-C. Serum C-reactive protein levels decreased; and
endothelium-dependent vascular responses improved.
Reproductive outcomes:
Signiﬁcant decreases in serum T, although no change in FSH and LH levels. Hirsutism score
decreased signiﬁcantly after treatment. 77.4% of women reverted to regular menstrual cycles.
Levels of SHBG increased signiﬁcantly after treatment.
Reference: Dereli et al. [86]
Patient proﬁle: Nonobese PCOS (n = 20/group)
PPAR agonist: Rosiglitazone (2mg/day or 4mg/day for 8 months)
Metabolic outcomes:
75% of women in the 2 mg group and 95% in the 4 mg group achieved normal glucose tolerance.
Improved insulin resistance in a dose-related fashion, without adverse events or liver enzyme
elevations.
Reproductive outcomes:
Decreased free-T levels were better in the 4mg group than the 2 mg group, and 70% of
women in the 2mg group and 85% of women in the 4mg group achieved ovulatory
menses.
Reference: Mehta et al. [87]
Patient proﬁle: Obese PCOS (n = 9)
PPAR agonist: Pioglitazone (45mg/day for 20 weeks)
Metabolic outcomes: Signiﬁcant improvement in insulin sensitivity
Reproductive outcomes:
LH levels, LH pulse frequency and amplitude, as well as gonadotropin responses to GnRH were
not inﬂuenced.
Reference: Ortega-Gonz´ alez et al. [88]
Patient proﬁle: Obese, insulin resistant PCOS (n = 25)
PPAR agonist: Pioglitazone (30mg/day for 6 months)
Metabolic outcomes:
Body weight, BMI, and WHR increased signiﬁcantly. Fasting insulin and insulin AUC during a
2-h OGTT decreased. Insulin resistance decreased and insulin sensitivity increased after
treatment with either pioglitazone or metformin received by control group.
Reproductive outcomes:
Hirsutism, free-T and androstenedione declined to a similar extent after treatment
with either drug. Treatment with both drugs was associated with the occurrence of
pregnancy
Reference: Sepilian and Nagamani [89]
Patient proﬁle: Obese insulin resistant PCOS (n = 12)
PPAR agonist: Rosiglitazone (4mg/day for 6 months)
Metabolic outcomes: Fasting insulin, insulin AUC, fasting glucose, and glucose AUC signiﬁcantly decreased. No
signiﬁcant change in BMI
Reproductive outcomes:
Both total-T, free-T and DHEA-S levels decreased signiﬁcantly. No signiﬁcant change in LH
levels. Levels of SHBG increased signiﬁcantly after treatment, 91.7% of women reverted to regular
ovulatory cycles during the treatment periodCadence E. Minge et al. 9
of enzymatic expression and/or activity in primary
porcine thecal cells or human cell lines [106–108].
(4) P450 aromatase (P450arom): aromatises androgen
precursor to estradiol, and is expressed by ovar-
ian granulosa [109]a n dl u t e a l[ 110] cells. Although
there is no correlation between the expression of the
P450arom enzyme and PPARG itself during follicu-
logenesis, many reports have described the down-
regulation of P450arom following TZD exposure in
human ovarian cell cultures [13, 111–113].
Takentogether,theseﬁndingsprovidestrongevidenceforthe
direct eﬀect of TZD administration and PPARG activation
onovarianhormonalsynthesisandsecretion.Speciﬁcallythe
following.
(1) Androgen: TZDs found to inhibit LH- and insulin-
stimulated androgen biosynthesis by puriﬁed porcine
thecal [108], and mixed human ovarian [98] cells.
They have also been found to reduce plasma testos-
terone levels in women with PCOS [76, 77, 81–84, 86,
89, 91, 97, 114, 115].
(2) Estrogen: While it is accepted that TZDs indeed inﬂu-
ence estrogen secretion, estrogenic responses to TZDs
appear to be dependent on confounding factors such
as species, age, and endocrine setting. For instance,
TZDs have been found to increase estradiol secretion
[2], and decrease estradiol production [116]. PPARG
activation by TZDs and phthalate toxins are believed
to mediate the antiestrogenic eﬀects of these agents in
cultured rat granulosa cells [116], and TZDs have also
been found to suppress stimulated estradiol secretion
in human granulosa cell cultures [98].
(3) Progesterone: As for estrogen, progesterone responses
to PPARG activation via natural or endogenous lig-
andsareunclear,andareprobablyregulatedbyspecies,
and stage of folliculogenesis. Most publications inves-
tigating a range of species, including primary bovine,
ovine, porcine, or rodent cell cultures, report increases
in progesterone secretion following administration of
PPARG activators in vitro [2, 8–10], whilst some oth-
ers suggest inhibition of stimulated progesterone se-
cretion by porcine granulosa cells [14].
The net inﬂuence of TZD treatment on ovarian PPARG
activation and subsequent steroidogenesis in vivo remains
poorly deﬁned across all species investigated. The most con-
clusive evidence for an advantageous outcome on hormonal
(speciﬁcally androgen) proﬁle following treatment is ob-
served in women with PCOS, as overviewed in Table 2.A s
a result, increasing attention may be paid towards the appli-
cation of these drugs in such conditions of signiﬁcant hor-
monal perturbations.
Rosiglitazone and pioglitazone are currently listed as a
Pregnancy Category C drug (i.e., not tested for use during
human pregnancy), and some side eﬀects of TZD admin-
istration, such as weight gain, ﬂuid retention (reviewed in
[117]), and possible bone demineralisation [118], preclude
their widespread use during pregnancy. However, in vitro
treatment of 2 cell mouse embryos, or in vivo treatment of
pregnant mice with rosiglitazone was not found to impact
upon normal blastocyst development, or litter rates and sizes
[119]. In situations where conception has occurred follow-
ingTZDtreatmentforPCOS,noadversefetaloutcomeshave
been observed [88, 96, 120]. Also in a recent study, examin-
ing tissue obtained from women with scheduled pregnancy
terminations, it was found that placental transfer of mater-
nally administered rosiglitazone to fetal tissues is minimal in
the ﬁrst 10 weeks of pregnancy [121].
4. MECHANISMS: PPARG REGULATION
OF METABOLIC AND IMMUNE FACTORS
INFLUENCING FEMALE FERTILITY
PPARG is known to regulate many pathways involving in-
sulin sensitivity, glucose metabolism, adipokine signalling,
lipid uptake and metabolism, and secretion of inﬂammatory
mediators. As a result, PPARG is being revealed as a key me-
diator of the fundamental metabolic and immune contribu-
tions that are required for normal female fertility.
4.1. Insulinsensitivity
Normal insulin sensitivity and subsequently eﬃcient metab-
olism of glucose are essential for healthy reproduction in the
female. Conditions of hyperinsulinemia can interfere with
normal ovarian cell function or be indirectly associated with
other hormonal conditions detrimental to optimal fertility
[122–124]. Also, exposure to high levels of glucose can have
ad e l e t e r i o u se ﬀect on the oocyte [125, 126]. By normalis-
ing peripheral insulin signalling, PPARG activation can cir-
cumvent many of these adverse eﬀects of hyperinsulinemia,
as well as those detrimental outcome associated with persis-
tently elevated blood glucose levels.
The genetic studies detailed above, and the pharmacoki-
netics of TZD treatment improving insulin sensitivity are
both consistent with a direct role for PPARG in the regu-
lation of cellular insulin utilization. Despite this, it remains
to be determined exactly how TZD treatment and subse-
quent PPARG activation impacts gene expression directly re-
lated to insulin signalling and glucose uptake (through genes
such as the insulin receptor (IR), IR-substrates, and glucose
transporters), as a range of conﬂicting results have emerged.
Suggested mechanisms include increases in glucosetransport
protein 4 (GLUT4), stimulation of phosphatidyl-3-kinase
andmodiﬁed phosphorylation of insulin receptor substrates
[127–133]. In addition, it is well accepted that activation of
PPARG does improve not only basal hepatic glucose secre-
tion, but also peripheral insulin-stimulated glucose uptake,
potentially indirectly via reduction of FFA, TNFα, plasmino-
gen activator inhibitor-1, and other autocrine/endocrine sig-
nalling molecules which otherwise interfere with eﬃcient in-
sulin signalling (reviewed in [134]). In this way, PPARG acti-
vation may improve female infertility exacerbated by obesity
and insulin resistance [25, 135–141].
New reports are also describing some of the ﬁrst investi-
gations into the ovarian-speciﬁc responses to TZD that facil-
itateinsulin sensitivity in thistissue. TheworkofSeto-Young
et al. [103] has shown that ovarian cells directly respond to10 PPAR Research
TZDs to increase transcription of insulin signalling compo-
nents including IR alpha and beta subunits and IRS-1, which
would subsequently provide more eﬃcient signal transduc-
tion and cellular response to insulin.
4.2. Adipokines:leptinandadiponectin
Producedprimarilybyadiposetissue,leptinandadiponectin
are “adipokines” with contrasting actions on insulin sensi-
tivity. Whilst other adipokines such as visfatin and retinol-
binding protein 4 (RBP-4) are also linked with insulin sen-
sitivity [142, 143] and the incidence of PCOS [144, 145],
leptin and adiponectin are of particular interest to those in-
vestigating female reproduction as it is known their pres-
ence can be detected by ovarian cells which express leptin
and adiponectin receptors. In addition, although only the
adiponectin promoter has been shown to contain a PPRE
[146], transcriptional activity of both leptin and adiponectin
genes is known to be decreased and increased, respectively,
in the presence of PPARG-activating ligands [147–151]. In
this way, they can operate as secondary messengers of signals
initiated by PPARG activation.
Leptin receptors are present in the granulosa and thecal
layers of the ovary [152, 153], and have been shown to be
cyclically regulated [154]. Leptin appears to inﬂuence ovar-
ian gonadotropin and steroid secretion [152, 153, 155], and
aﬀect oocyte quality and developmental potential [156, 157].
Adiponectin receptors AdipoR1 and AdipoR2 are also
both expressed by ovarian tissue [158] and adiponectin it-
self has been identiﬁed within the follicular ﬂuid of devel-
oped follicles in similar concentrations to that observed in
theserum[159].Adiponectinappearstobeinvolvedinmany
processes including those essential for ovulation, such as in-
duction of COX-2 and prostaglandin E synthase expression
in ovarian granulosa cells [159].
As the entire range of leptin and adiponectin eﬀects on
ovariancellularfunctions,including theoutcomesofPPARG
activation(includingenhancementofinsulinsensitivity),are
gradually established, it is likely we will ﬁnd that the im-
provements to reproductive proﬁles and ovarian function of
sub-fertile or infertile women treated with TZDs are me-
diated, at least in part, through modulation of these two
adipokines.
4.3. Lipiduptake:CD36andSCARB1
PPARG has a critical role in the regulation of adipocyte dif-
ferentiation [94]. Among the best characterised PPARG tar-
get genes are those involved in lipid metabolism, includ-
ing phosphoenolpyruvate carboxykinase [160], lipoprotein
lipase [161], fatty acid binding protein [162, 163], and CD36
and SCARB1 [164, 165]. CD36 and SCARB1, class B scav-
enger receptors that mediate the endocytosis or selective
cholesterol uptake from oxLDL and HDL lipoproteins, are
also both strongly expressed by the ovary. The CD36 anti-
genis highly expressed by granulosa cells of preantral and
earlyantral follicles, with moderatestaining also evident in
the vascular thecal layers [166].In this context, CD36 has
been reported as a facilitator of thrombospondins-1 and -2
activities [166, 167], inﬂuencing cell adhesion, wound heal-
ing, and angiogenesis [168, 169]; important components of
the tissue and cellular changes that occur during the ovarian
cycle. CD36 is upregulated following activation of PPARG in
macrophages [164, 170], and a summary of PPARG control
ofgeneexpression[171]suggestedthismightactasapositive
feedback mechanism, such that more potential PPARG lig-
ands can be imported, enhancing expression of both PPARG
and CD36.
Ovarian SCARB1 expression appears to be strongly as-
sociated with HDL-cholesterol ester requirement for pro-
duction of androgen for aromatase-mediated conversion to
estradiol by the granulosa cells, and progesterone synthesis
by luteal cells. Thecal cells consistently express high levels of
SCARB1 at all stages of both healthy and atretic follicle de-
velopment [172], and high expression is also found within
luteal structures [173].
In these respects, PPARG activation may have profound
inﬂuenceonovarianfunctionthroughtheregulationofthese
genes or others regulating lipid metabolism, by aﬀecting
availability of substrate for hormone synthesis, and the re-
modelling of tissue structures required for oocyte release,
luteinization, and luteolysis.
4.4. Suppressionofchronicinﬂammation
An important role for PPARG is the suppression of immune
cell synthesis and secretion of proinﬂammatory mediators
[174–182]( r e v i e w e d[ 183–185] ) .T h er o l eo ft h ei m m u n e
system in female fertility is critical, both systemically, and lo-
cally at the ovarian level.
In addition, there are also interesting correlations be-
tween the development of adiposity, insulin resistance and,
chronic inﬂammation. Increased serum concentrations of
TNF, NO, and IL-6 are strongly associated with obesity [186,
187], and proinﬂammatory cytokines sourced from adipose
tissue including TNF, and IL-6 are among several important
factors that participate in the development of insulin resis-
tance and type 2 diabetes mellitus [188–191]. Interestingly,
togetherwithcentraladiposityandinsulinresistance,wealso
ﬁnd aspects of systemic inﬂammation independently asso-
ciated with impaired female fertility and PCOS [192, 193].
PPARG is implicated in improvements to the systemic in-
ﬂammation observed in obese and insulin resistant individ-
uals treated with TZDs. These studies describe reductions
in serum C-reactive protein, IL-6, and soluble TNF recep-
t o r2[ 194–198]. Other studies investigating the chronically
inﬂamed proﬁle of PCOS patients support these ﬁndings, re-
porting that in addition to restoring menstrual cyclicity and
improving markers of hyperandrogensism, TZD treatment
is able to lower circulating C-reactive protein levels and the
number of circulating leukocytes [75, 85].
4.5. Ovarianmacrophages
Macrophages, dendritic cells, lymphocytes, and neutrophils
have unique roles in the context of ovarian physiology, and
are essential for the normal regulation of ovulation and
control of the reproductive cycle [5, 199–201]. MacrophageCadence E. Minge et al. 11
distribution and numbers within the ovary varies across the
cycle, inﬂuenced by gonadotrophins and ovarian steroido-
genic hormones. Resident macrophages are present in the
theca and stroma of the ovary during the late stages of fol-
liculogenesis [202]. Once the LH surge commences prior to
ovulation, there is a massive recruitment of new leukocytes
from the circulation into the theca of the preovulatory folli-
cle [202, 203], where they function to release proinﬂamma-
tory cytokines and mediators assisting the breakdown of the
ovarianepitheliumatovulation. Theirpresencepersistsuntil
after ovulation, further increasing in number in the develop-
ing and regressing corpus luteum [204].
Ovarian macrophages maintain high levels of PPARG
transcriptexpressionuntilasigniﬁcantreductioninresponse
to the proovulatory LH surge [1]. Immediately following
ovulation, expression is restored to high preovulatory lev-
els [1]. In vitro treatment of puriﬁed ovarian macrophages
withtheTZDtroglitazonehasbeenshowntosigniﬁcantlyal-
ter proinﬂammatory gene expression [1]. Speciﬁcally, these
cells respond to TZD exposure by signiﬁcantly suppressing
mRNA production of NOS2 (or inducible Nitric Oxide Syn-
thase, iNOS), the enzyme that catalyses the reaction produc-
ing the potent vasodilator, nitric oxide (NO). In the human,
NOseemstodirectfollicularselectionandmaturation[205],
and application of this NO property to IVF patients, deemed
“poor responders”, has been found to increase the number of
oocytes retrieved [206]. This is an indication that recruited
andspecializedovarianmacrophagescanpotentiallyrespond
directly to TZDs administered systemically, and can regu-
late the availability of ovulatory mediators. Such responses
parallel the anti-inﬂammatory eﬀects of PPARG activation
in nonovarian-activated macrophages [171], but was here
found to be speciﬁc to macrophages closely associated with
the ovarian environment (distinct to those located in the
peritoneal cavity for instance). This illustrates the unique in-
ﬂuenceoftheovarianmilieuonnormalPPARGfunctionand
eﬀects.
5. CONCLUSIONS
Many diverse endocrine and metabolic components pro-
foundly inﬂuence female fertility, including hormone pro-
duction as well as the development and ovulation of healthy
oocytes. The role of PPARG in these events is two-fold.
PPARG activation of transcription has outcomes operating
both directly within the ovarian structure itself, and also in-
directly through inﬂuences on other tissue systems such as
the adipose tissue and immune cells (Figure 3). In this way,
PPARG controls key signals regulating the capacity for nor-
mal reproduction. As PPARG is able, and required, to reg-
ulate many of these actions, it is important that the roles
of PPARG be carefully considered as new concepts develop
regarding the eﬀects of dietary supplements such as PU-
FAs, which are PPARG ligands, and the consequences of
increased immunological activation, such as occurs during
obesity.Asthehealthcrisissurroundingtheobesityepidemic
widens to include the damaging eﬀects on female fertility,
it is important to remember the systemic implications of
metabolism and immune regulation on female fertility, and
Metabolic
signals
Immune
contributions
Ovarian
function
PPARG
TZD
Figure 3: Schematic summarising the developing concept of
PPARGinﬂuenceonovarianfunctionandfemalefertility.PPARGis
abletostronglyinﬂuencetheactivityofovariancellsdirectly,inpar-
ticular steroidogenesis and tissue remodelling. In addition, PPARG
can further inﬂuence ovarian function via regulation of external
metabolic signals and immune cell contributions.
to consider the role of PPARG in coordinating these con-
tributions. Tremendous opportunity exists for those inter-
ested in elucidating further the exciting interactions between
PPARG and female fertility. Publication of the most exten-
sive list to date of all genes containing potential PPREs in
their promoter regions [207]w i l lp r o v i d eav a l u a b l et o o lf o r
such research, as many identiﬁed genes have known func-
tionswithinthecontextofovarianphysiologyandpathology,
in addition to characterized roles in other tissues, including
macrophages and adipose tissue.
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